Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 4 · 57.1%Low 2 · 28.6%Moderate 1 · 14.3%High 0 · 0%

50% or greater reduction in seizure frequency · people with drug‐resistant focal epilepsy

Carisbamate probably leads to higher 50% or greater reduction in seizure frequency (responder rate) compared with placebo (moderate certainty).

1 finding from 1 review

Carisbamate add‐on therapy for drug‐resistant focal epilepsy 2021 · Cochrane Headline outcomes only
RR 1.36 [1.14, 1.62]
4 studies · 2211 participants
Moderate

Seizure freedom · people with drug‐resistant focal epilepsy

It is very uncertain whether carisbamate changes seizure freedom compared with placebo (very low certainty).

1 finding from 1 review

Carisbamate add‐on therapy for drug‐resistant focal epilepsy 2021 · Cochrane Headline outcomes only
RR 2.43 [0.84, 7.03]
1 study · 540 participants
Very low

Treatment withdrawal · people with drug‐resistant focal epilepsy

It is very uncertain whether carisbamate changes treatment withdrawal for any reason compared with placebo (very low certainty).

1 finding from 1 review

Carisbamate add‐on therapy for drug‐resistant focal epilepsy 2021 · Cochrane Headline outcomes only
RR 1.32 [0.82, 2.12]
4 studies · 2211 participants
Very low

Withdrawals due to adverse events · people with drug‐resistant focal epilepsy

It is very uncertain whether carisbamate changes treatment withdrawal due to adverse events compared with placebo (very low certainty).

1 finding from 1 review

Carisbamate add‐on therapy for drug‐resistant focal epilepsy 2021 · Cochrane Headline outcomes only
RR 1.8 [0.78, 4.17]
4 studies · 2211 participants
Very low

Participants who experienced any adverse event Adverse event regardless of severity · people with drug‐resistant focal epilepsy

Carisbamate showed no clear difference in proportion of participants who experienced atleast 1 adverse event compared with placebo (low certainty).

1 finding from 1 review

Carisbamate add‐on therapy for drug‐resistant focal epilepsy 2021 · Cochrane Headline outcomes only
RR 1.1 [0.93, 1.3]
2 studies · 1084 participants
Low

Dizziness · people with drug‐resistant focal epilepsy

It is very uncertain whether carisbamate changes adverse events: dizziness compared with placebo (very low certainty).

1 finding from 1 review

Carisbamate add‐on therapy for drug‐resistant focal epilepsy 2021 · Cochrane Headline outcomes only
RR 2.06 [1.23, 3.44]
4 studies · 2211 participants
Very low

Drowsiness/somnolence (Event rate during treatment, length of treatment varied across trials) · people with drug‐resistant focal epilepsy

Carisbamate may leads to higher adverse events: somnolence compared with placebo (low certainty).

1 finding from 1 review

Carisbamate add‐on therapy for drug‐resistant focal epilepsy 2021 · Cochrane Headline outcomes only
RR 1.82 [1.28, 2.58]
4 studies · 2211 participants
Low